Panacea Acquisition Corp. II
Status: Liquidated
U=S
IPO Proceeds, $M | $172.50M |
---|---|
IPO Date | Apr 7, 2021 |
CEO | Oleg Nodelman |
Left Lead | Cowen |
IPO Cash in Trust | 100.0% |
SPAC Tenor | 24+(3) |
IPO Sector |
Healthcare
Biotechnology in North America or Europe |
IPO Geography | Global |
Target Company | N/A |
Deal Announced | N/A |
Deal Size, $M | TBD |
Deal Sector | TBD |
Deal Geography | TBD |
SEC Filings | www.sec.gov |
Approval Vote | TBD |
Amendment Vote | TBD |
Closing Date | Apr 19, 2023 |
PANA
Price | |
---|---|
Volume, 3-month avg. | N/A |
Price | |
---|---|
Volume, today | |
Volume, 3-month avg. | N/A |
Price | |
---|---|
Volume, today | |
Volume, 3-month avg. | N/A |
Price | |
---|---|
Volume, today | |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Panacea Acquisition Corp. II:
- Structure and cap table
- 9 directors & officers
- 5 filings and events
- 1 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Oleg Nodelman | 44 | CEO & Chairman |
Scott Perlen | 46 | CFO |
Scott Platshon | 30 | COO |
Caroline Stout | 30 | CIO |
Sarah Marriott | 44 | Secretary and Director |
Douglas Giordano | 59 | Director |
Nina Kjellson | 47 | Director |
Praveen Tipirneni, M.D. | 53 | Director |
Douglas E. Williams, Ph.D. | 63 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
Cowen | BR | 15,000,000 | units |
15,000,000 | units | ||
Up-Front UW fee | 2.00 | % | |
Deferred UW fee | 3.50 | % |
Sign in to view more advisor data.
Filings
Sign in to view 5 filings.